Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Iron-Deficiency | 4 | 2024 | 136 | 2.260 |
Why?
|
| Thrombosis | 5 | 2024 | 501 | 1.890 |
Why?
|
| Hemophilia A | 2 | 2024 | 24 | 1.530 |
Why?
|
| Anticoagulants | 7 | 2024 | 564 | 1.480 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 49 | 1.470 |
Why?
|
| Venous Thrombosis | 2 | 2021 | 167 | 1.210 |
Why?
|
| Hemorrhage | 2 | 2023 | 473 | 1.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 540 | 1.150 |
Why?
|
| Fibroblasts | 2 | 2021 | 820 | 1.030 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2022 | 51 | 0.920 |
Why?
|
| von Willebrand Diseases | 1 | 2025 | 50 | 0.910 |
Why?
|
| Postoperative Hemorrhage | 1 | 2025 | 80 | 0.900 |
Why?
|
| Iron | 2 | 2024 | 296 | 0.860 |
Why?
|
| Tonsillectomy | 1 | 2025 | 112 | 0.830 |
Why?
|
| Thrombolytic Therapy | 2 | 2024 | 202 | 0.800 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2021 | 95 | 0.800 |
Why?
|
| Health Information Systems | 1 | 2022 | 31 | 0.760 |
Why?
|
| Warfarin | 1 | 2023 | 112 | 0.750 |
Why?
|
| Blood Coagulation Factors | 1 | 2021 | 31 | 0.720 |
Why?
|
| Thrombin | 1 | 2021 | 57 | 0.710 |
Why?
|
| May-Thurner Syndrome | 1 | 2021 | 4 | 0.700 |
Why?
|
| Dietary Supplements | 1 | 2024 | 438 | 0.660 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 99 | 0.650 |
Why?
|
| Factor X | 1 | 2020 | 4 | 0.650 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 112 | 0.640 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 159 | 0.640 |
Why?
|
| Anemia | 1 | 2023 | 336 | 0.640 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 150 | 0.630 |
Why?
|
| Blood Coagulation | 1 | 2020 | 122 | 0.600 |
Why?
|
| Lower Extremity | 1 | 2021 | 180 | 0.600 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2019 | 20 | 0.600 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2019 | 162 | 0.560 |
Why?
|
| Endothelial Cells | 1 | 2021 | 505 | 0.560 |
Why?
|
| Neutropenia | 1 | 2019 | 198 | 0.540 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 222 | 0.520 |
Why?
|
| Febrile Neutropenia | 1 | 2016 | 15 | 0.520 |
Why?
|
| Pediatric Obesity | 1 | 2022 | 408 | 0.510 |
Why?
|
| Cardiac Catheterization | 1 | 2020 | 620 | 0.500 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 191 | 0.500 |
Why?
|
| Infant | 10 | 2025 | 12762 | 0.490 |
Why?
|
| Adolescent | 12 | 2025 | 19936 | 0.480 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 588 | 0.470 |
Why?
|
| Stroke | 1 | 2022 | 1005 | 0.440 |
Why?
|
| Child | 13 | 2025 | 25062 | 0.420 |
Why?
|
| Bacterial Infections | 1 | 2016 | 308 | 0.410 |
Why?
|
| Humans | 24 | 2025 | 126089 | 0.390 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1568 | 0.350 |
Why?
|
| Prothrombin | 2 | 2021 | 21 | 0.340 |
Why?
|
| Infant, Newborn | 6 | 2025 | 8358 | 0.340 |
Why?
|
| Retrospective Studies | 7 | 2025 | 16770 | 0.290 |
Why?
|
| Child, Preschool | 6 | 2025 | 14329 | 0.280 |
Why?
|
| Female | 11 | 2025 | 67915 | 0.260 |
Why?
|
| Cell Line | 2 | 2021 | 2565 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 2495 | 0.230 |
Why?
|
| Iron, Dietary | 1 | 2024 | 14 | 0.220 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 48 | 0.210 |
Why?
|
| Factor XIII Deficiency | 1 | 2024 | 4 | 0.210 |
Why?
|
| Male | 8 | 2025 | 62089 | 0.210 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2024 | 10 | 0.210 |
Why?
|
| Postthrombotic Syndrome | 1 | 2023 | 2 | 0.210 |
Why?
|
| Physician Executives | 1 | 2024 | 35 | 0.210 |
Why?
|
| Thrombectomy | 1 | 2024 | 105 | 0.210 |
Why?
|
| Menorrhagia | 1 | 2024 | 81 | 0.200 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1025 | 0.200 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 45 | 0.200 |
Why?
|
| Young Adult | 4 | 2022 | 9616 | 0.200 |
Why?
|
| Aortic Diseases | 1 | 2024 | 162 | 0.190 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 65 | 0.190 |
Why?
|
| Craniocerebral Trauma | 1 | 2024 | 137 | 0.190 |
Why?
|
| ADAM Proteins | 1 | 2022 | 83 | 0.190 |
Why?
|
| Nutritional Status | 1 | 2024 | 298 | 0.180 |
Why?
|
| Carbohydrate Epimerases | 1 | 2021 | 1 | 0.180 |
Why?
|
| Ketone Oxidoreductases | 1 | 2021 | 2 | 0.180 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2021 | 6 | 0.180 |
Why?
|
| Thrombomodulin | 1 | 2021 | 17 | 0.180 |
Why?
|
| Factor V | 1 | 2021 | 15 | 0.180 |
Why?
|
| Factor Xa | 1 | 2021 | 14 | 0.180 |
Why?
|
| Carboxy-Lyases | 1 | 2021 | 13 | 0.180 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2022 | 50 | 0.180 |
Why?
|
| Antithrombin III | 1 | 2021 | 26 | 0.180 |
Why?
|
| Treatment Outcome | 3 | 2021 | 12328 | 0.180 |
Why?
|
| Disease Management | 2 | 2024 | 533 | 0.170 |
Why?
|
| Proteolysis | 1 | 2021 | 175 | 0.170 |
Why?
|
| Factor VII | 1 | 2020 | 16 | 0.160 |
Why?
|
| Factor IX | 1 | 2020 | 15 | 0.160 |
Why?
|
| Thromboplastin | 1 | 2020 | 19 | 0.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 200 | 0.160 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 103 | 0.160 |
Why?
|
| Factor VIII | 1 | 2020 | 47 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2023 | 1187 | 0.150 |
Why?
|
| Prognosis | 2 | 2025 | 4709 | 0.150 |
Why?
|
| Cytoplasm | 1 | 2020 | 250 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 1 | 2020 | 307 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2021 | 745 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 786 | 0.140 |
Why?
|
| Algorithms | 1 | 2024 | 1619 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 143 | 0.130 |
Why?
|
| Hematopoiesis | 1 | 2019 | 200 | 0.130 |
Why?
|
| Gene Expression | 1 | 2021 | 1485 | 0.130 |
Why?
|
| Skin | 1 | 2020 | 515 | 0.130 |
Why?
|
| Models, Biological | 1 | 2021 | 1370 | 0.130 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 29 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5050 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1231 | 0.120 |
Why?
|
| Standard of Care | 1 | 2016 | 133 | 0.120 |
Why?
|
| Triage | 1 | 2016 | 143 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2024 | 4920 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 727 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 196 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3905 | 0.100 |
Why?
|
| Adult | 3 | 2022 | 30254 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2019 | 1520 | 0.090 |
Why?
|
| United States | 1 | 2024 | 11204 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2016 | 6093 | 0.060 |
Why?
|
| Factor XIII | 1 | 2024 | 7 | 0.050 |
Why?
|
| Hemostasis | 1 | 2023 | 72 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 316 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2022 | 788 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 677 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1227 | 0.030 |
Why?
|
| Incidence | 1 | 2024 | 3213 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2547 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 2600 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2772 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 3256 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 10397 | 0.020 |
Why?
|